The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...
(Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory panel will meet on Friday to review data on the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE, with a vote ...
(Reuters) -Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE, more than five years after both firms formed an alliance that yielded a vaccine to combat the ...
The COVID-19 vaccine maker reported sales of $1.78 billion (1.52 billion euros), compared to 1.24 billion euros a year ago, beating the consensus of $1.19 billion. The increase was primarily driven by ...
The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results